Literature DB >> 7901226

Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate.

R Gabizon1, Z Meiner, M Halimi, S A Ben-Sasson.   

Abstract

PrPSc is the only known component of the scrapie prion. The difference between PrPSc and its normal isoform PrPc is probably conformational, since no difference has been found in the amino acid sequence or postranslational modifications between both proteins. Heparan sulfate (HS) has been shown to be a component of amyloid plaques in a number of diseases including the prion diseases. We now present evidence that PrP can specifically bind to heparin-like compounds and that this interaction might have a physiological significance. HS can increase the concentration of PrP in normal neuroblastoma cells, whereas low molecular weight heparin (LMWH) does not. In contrast, LMWH and other heparin-like molecules, excluding HS, can inhibit the synthesis of PrPSc in scrapie infected cells and reverse their phenotype back to normal as judged by measurement of PrPSc by immunoblotting and by infectivity experiments. Whether an interaction between PrP and glycosaminoglycans plays a direct role in the conversion of PrPc into PrPSc remains to be established.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901226     DOI: 10.1002/jcp.1041570215

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  37 in total

1.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.

Authors:  M Horiuchi; B Caughey
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.

Authors:  C Wong; L W Xiong; M Horiuchi; L Raymond; K Wehrly; B Chesebro; B Caughey
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

3.  Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor.

Authors:  C Hundt; J M Peyrin; S Haïk; S Gauczynski; C Leucht; R Rieger; M L Riley; J P Deslys; D Dormont; C I Lasmézas; S Weiss
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 4.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

Review 5.  The role of the prion protein in the molecular basis for synaptic plasticity and nervous system development.

Authors:  Sandra E Encalada; Kenneth L Moya; Sylvain Lehmann; Ralph Zahn
Journal:  J Mol Neurosci       Date:  2007-06-14       Impact factor: 3.444

6.  A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner.

Authors:  Young Pyo Choi; Suzette A Priola
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 7.  The role of glycoproteins in neural development function, and disease.

Authors:  K C Breen; C M Coughlan; F D Hayes
Journal:  Mol Neurobiol       Date:  1998-04       Impact factor: 5.590

8.  Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion protein.

Authors:  Victoria A Lawson; Brooke Lumicisi; Jeremy Welton; Dorothy Machalek; Katrina Gouramanis; Helen M Klemm; James D Stewart; Colin L Masters; David E Hoke; Steven J Collins; Andrew F Hill
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

9.  Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Authors:  Tehila Mayer-Sonnenfeld; Dana Avrahami; Yael Friedman-Levi; Ruth Gabizon
Journal:  Cell Mol Neurobiol       Date:  2008-03-19       Impact factor: 5.046

10.  Heparan Sulfate and Heparin Promote Faithful Prion Replication in Vitro by Binding to Normal and Abnormal Prion Proteins in Protein Misfolding Cyclic Amplification.

Authors:  Morikazu Imamura; Naoko Tabeta; Nobuko Kato; Yuichi Matsuura; Yoshifumi Iwamaru; Takashi Yokoyama; Yuichi Murayama
Journal:  J Biol Chem       Date:  2016-11-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.